Short Interest in Immunic, Inc. (NASDAQ:IMUX) Declines By 11.9%

Immunic, Inc. (NASDAQ:IMUX) saw a large drop in short interest in the month of February. As of February 29th, there was short interest totalling 2,220,000 shares, a drop of 11.9% from the February 14th total of 2,520,000 shares. Based on an average daily volume of 943,800 shares, the days-to-cover ratio is currently 2.4 days.

Analyst Ratings Changes

Separately, StockNews.com raised Immunic from a “sell” rating to a “hold” rating in a research note on Monday, March 11th.

Hedge Funds Weigh In On Immunic

A number of institutional investors have recently made changes to their positions in IMUX. JPMorgan Chase & Co. raised its holdings in Immunic by 21.2% in the 1st quarter. JPMorgan Chase & Co. now owns 13,649 shares of the company’s stock valued at $154,000 after acquiring an additional 2,387 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Immunic by 30.6% in the 1st quarter. Rhumbline Advisers now owns 22,122 shares of the company’s stock valued at $250,000 after purchasing an additional 5,182 shares during the period. Northern Trust Corp grew its stake in shares of Immunic by 3.0% in the 1st quarter. Northern Trust Corp now owns 188,148 shares of the company’s stock valued at $2,126,000 after purchasing an additional 5,553 shares during the period. BlackRock Inc. grew its stake in shares of Immunic by 2.5% in the 2nd quarter. BlackRock Inc. now owns 377,503 shares of the company’s stock valued at $948,000 after purchasing an additional 9,061 shares during the period. Finally, Two Sigma Investments LP grew its stake in shares of Immunic by 3.4% in the 1st quarter. Two Sigma Investments LP now owns 290,668 shares of the company’s stock valued at $433,000 after purchasing an additional 9,603 shares during the period. 45.26% of the stock is currently owned by institutional investors.

Immunic Price Performance

NASDAQ IMUX remained flat at $1.31 during trading on Monday. The company’s stock had a trading volume of 461,847 shares, compared to its average volume of 1,136,473. Immunic has a one year low of $0.95 and a one year high of $3.11. The business’s 50 day simple moving average is $1.28 and its two-hundred day simple moving average is $1.29. The company has a market cap of $117.81 million, a P/E ratio of -0.62 and a beta of 2.07.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Thursday, February 22nd. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.03. On average, equities research analysts predict that Immunic will post -1 EPS for the current fiscal year.

About Immunic

Immunic, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 3 clinical for treatment of multiple sclerosis, including relapsing multiple sclerosis and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.